this post was submitted on 13 Jun 2023

22 points (100.0% liked)

Science

13082 readers

1 users here now

Studies, research findings, and interesting tidbits from the ever-expanding scientific world.

Subcommunities on Beehaw:

Space

Be sure to also check out these other Fediverse science communities:

This community's icon was made by Aaron Schneider, under the CC-BY-NC-SA 4.0 license.

founded 3 years ago

MODERATORS

22

FDA Panel Unanimously Endorses Lecanemab for Alzheimer's (www.medscape.com)

submitted 2 years ago by Dr_Cog to c/science

7 comments fedilink hide all child comments

you are viewing a single comment's thread
view the rest of the comments

[–] wjs018 1 points 2 years ago

Thanks for the explanation! I was curious how the targeting differed between the two mAbs and found a paper that explains:

Specifically, lecanemab mainly targets Aβ protofibrils, while aducanumab and other monoclonal antibodies favour highly aggregated forms of Aβ [5]. This differing target profile may also explain a substantially lower incidence of amyloid related imaging abnormalities, such as transient immunotherapy-related brain oedema and microbleeds, with lecanemab.

In other words, lecanemab seems to bind and remove Aβ before it aggregates, while other therapies (aducanumab) bind and then remove it after aggregation occurs.